Whalesbook
📉 The Financial Deep Dive
The Numbers:
Rainbow Children’s Medicare Limited announced its Q3 FY26 results, posting a healthy 11.9% year-on-year (YoY) revenue growth to ₹445.45 Crore (₹4,454.5 million). For the nine-month period ended December 31, 2025 (9M FY26), revenue climbed 8.5% YoY to ₹1,243.18 Crore (₹12,431.8 million).
EBITDA (Post Ind AS 116 & excluding other income) saw a 9.4% YoY rise in Q3 FY26, reaching ₹146.98 Crore (₹1,469.8 million). However, this growth came with a slight margin compression, as EBITDA margins dipped to 33.0% from 33.8% in the prior year period.
Profit After Tax (PAT) for Q3 FY26 increased by 7.2% YoY to ₹73.90 Crore (₹739.0 million). Correspondingly, PAT margins also saw a slight dip to 16.6% from 17.3% in Q3 FY25.
The Quality:
While revenue and absolute profit figures show robust growth, the slight compression in both EBITDA and PAT margins warrants attention. This suggests that while the company is increasing its top line and patient volumes, the cost of delivering care may be rising at a faster pace. The operational metrics, however, paint a positive picture for demand.
Operational Highlights & Strategic Moves:
The company reported significant operational momentum with an 18% YoY increase in IP Discharges and an 11% YoY rise in OP Consultations during Q3 FY26. Operational Beds also grew by 10.3% YoY to 25,605.
Strategic expansion is evident through the completion of acquisitions of Prashanthi Hospital in Warangal and Pratiksha Hospital in Guwahati. Furthermore, the company commenced operations of a new 100-bed hospital in Rajahmundry, Andhra Pradesh.
The appointment of Mr. Abrarali Dalal as the new Group Chief Executive Officer brings experienced leadership to steer future growth. His over 25 years of experience in healthcare leadership is expected to be a key asset.
The achievement of JCI (Joint Commission International) accreditation for its flagship hospitals and fertility center underscores a commitment to high-quality patient care and international standards.
🚩 Risks & Outlook
Specific Risks:
The primary risk lies in managing the projected margin compression. Continued increases in healthcare costs, staff salaries, and consumables could exert further pressure. The successful integration of acquired hospitals and the timely, efficient execution of the ambitious expansion plans adding approximately 790 beds over the next two fiscal years (in Coimbatore, Gurugram, and Pune) will be critical. Delays or cost overruns in these expansion projects could impact profitability.
The Forward View:
Investors will be closely watching the company's ability to manage its cost structure while executing its aggressive growth strategy. The focus will be on whether the operational efficiencies can offset cost inflation and improve margins in upcoming quarters. The performance of newly acquired and upcoming facilities, along with Mr. Dalal's leadership, will be key indicators to monitor.